NCR2 and plasma cell myeloma: In line with these PD1 blocking associated-improvement in NK cell in vitro and in vivo activity, NKp44, NKp46 and NKG2D were significantly enhanced, which may at least in part contribute to the PD1 blocking associated improvement of anti-myeloma activity of exNK cells.